Advancements in Population Health Strategies for Cardiovascular Risk Management

Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and Lp(a) (lipoprotein a), drive atherosclerotic heart disease.

Michael D. Shapiro, DO, reviews and discusses the different guidelines and recommendations on Lp(a) testing.

Jaime Murillo, MD, explores genetic inheritance patterns of Lp(a) from childhood to adulthood, highlighting stability, factors affecting measurement, and awareness challenges among those in the health care community.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, explain the importance of the global Lp(a)HERITAGE study, emphasizing prevalence of elevated Lp(a) among different populations and the evolving approach to assessing Lp(a) levels.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, discuss the disproportionately high Lp(a) levels seen across different demographic groups, and the need for increased screening and treatment to mitigate the risk of cardiovascular disease.

Michael D. Shapiro, DO, and Jaime Murillo, MD, discuss the implications of high Lp(a) levels in the US population, racial disparities, and tailored interventions for high-risk groups.

Experts discuss the integration of Lp(a) testing into cardiovascular risk assessment, and refining preventive strategies and statin use in specific groups.

Experts discuss strategies for integrating Lp(a) testing into clinical practice across organizations, leveraging new therapies, education, and quality measures for improved patient care.

Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, provide insights into upcoming Lp(a)-targeted treatments and current management strategies for improved cardiovascular outcomes.

Experts provide insights for health care decision makers on the importance of Lp(a) level assessment to help mitigate the risk of cardiovascular disease, including actionable steps for seamless integration.